Trooperstocks
3年前
HippoFi Inc. (OTC:ORHB) mainly operates across three business segments: digital payments, artificial intelligence, and regenerative therapeutics. Its flagship subsidiary unit, PUR Biologics, is involved in the regenerative therapeutics space. In recent times, regenerative therapeutics have become a source of hope for people who suffer from tissue and organ failures due to a range of factors like age, trauma, and diseases.
logytwo
3年前
HippoFi is Finalizing Definitive Agreements to Join Forces with an Industry Giant to Revolutionize the Spinal Biologic Market
IRVINE, CA / July 25, 2023 / HippoFi, Inc. (OTCPK:ORHB) - HippoFi, a healthcare technology and innovation firm focused on the development, acquisition, and sale of biologic products used for Spine surgery, has entered the final phase of negotiations for definitive agreements as part of the confidential Letter of Intent with a highly respected leader in the industry.
The Company plans to announce the intended long-term strategic relationship and asset acquisition soon, aiming to redefine the spinal biologic market. The strategic alliance will leverage the extensive expertise of both companies to create a breakthrough biomaterial that has already shown promise to be a game-changing solution for bone growth.
“The companies will work together with the intent of near-term product commercialization to bring this new technology to healthcare providers and help improve patient’s functional outcomes,” states, CJ Wiggins, Executive Chairman and CEO of HippoFi.
To learn more about PUR Biologics' full line of biologic products, visit: www.PURbiologics.com
logytwo
3年前
HippoFi Anticipates a New Strategic Partnership as the Company Prepares to Launch PURmarrow 360, a Patented Stem Cell Harvesting Device
IRVINE, CA / July 24, 2023 / HippoFi, Inc. (OTCPK:ORHB) a leading healthcare technology company and authority in spinal biologics, focused on the development and distribution of innovative biotech products, is proud to announce that over the last 6 months, while under a confidential Letter of Intent in a strategic partnership, HippoFi has designed and formulated a strategic launch of the PURmarrow 360 bone marrow aspirate (BMA) device throughout the United States.
This product is a natural extension to our robust product line, allowing surgeons to safely and selectively capture the highly desired cells from a patient’s own BMA during surgery. This rich marrow enhances the effectiveness of PUR’s products by combining the stem cells, growth factors, and proteins, helping to supercharge bone growth in spine surgeries and improve patient healing.
“As a market leader in innovation, we believe PURmarrow 360 is in the patient’s best interest, as the purity and genetic makeup of their own living cells is unmatched. PURmarrow 360 is simple to use, without requiring centrifugation, making it easy for spine surgeons to incorporate in every spine surgery.” shared, CJ Wiggins, Executive Chairman and CEO of HippoFi.
To learn more about PUR Biologics' full line of biologic products, visit: www.PURbiologics.com
logytwo
3年前
Wilmington, Delaware, United States, June 19, 2023 (GLOBE NEWSWIRE) — The global spine biologics market is anticipated to be valued at US$ 3.5 billion by 2031, expected to incline at a CAGR of 4.2% from 2023 to 2031. An increase in the geriatric population base and a rise in the frequency of spine abnormalities are propelling the market.
The development and commercialization of advanced stem cell therapies are also bolstering the market. Stem cells have shown promising potential in promoting tissue regeneration and improving patient outcomes in spinal fusion surgeries. Various companies have developed innovative bone graft substitutes using biologic materials.
Access the sample report in PDF format @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17444
[Discover a detailed summary of the report, encompassing market size, forecast, and research methodology]
For instance, in 2021, Medtronic offered INFUSE Bone Graft, which utilizes a recombinant human bone morphogenetic protein (rhBMP-2) to stimulate bone growth in spinal fusion surgeries. This product eliminates the need for harvesting bone from the patient’s body and has shown positive clinical outcomes.
The adoption of these bone graft substitutes is increasing, as these offer advantages such as ease of use, reduced risk of infection, and improved patient outcomes. Research and development efforts are focused on enhancing the efficacy and safety of spine biologics, which is expected to provide opportunities for companies to develop novel products and therapies during the forecast period.
Key Takeaways from the Market Study
As of 2022, the global spine biologics market was valued at US$ 2.4 billion
A Y-o-Y growth rate of 4.1% is expected for the market in 2023, with an anticipated valuation of US$ 2.5 billion
From 2023 to 2031, the global spine biologics market is likely to expand by 1.4x
By product, bone allograft-based spine biologics are likely to gain significant momentum until 2033
Preference for minimally invasive spine biologics surgeries is inclining among patients
By end user, hospitals are expected to remain the primary site for conducting spine biologics
Get Customization on this Report for Specific Research Solutions at https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=17444
Spine Biologics Market: Prominent Growth Drivers
Increase in the geriatric population and rise in frequency of spine abnormalities are propelling the market. Surge in preference for minimally invasive procedures, rise in incidence of degenerative spine disorders, and surge in treatment cost are driving market expansion
Benefits of biologics such as faster recovery, minimal postoperative time, and ability to activate cellular growth is another major factor fueling global spine biologics market demand.
Industry players have been focusing on the development of technologically advanced and cost-effective products to gain a competitive advantage. For instance, in 2018, NuVasive expanded its biologics business line with the launch of AttraX Scaffold.
Spine Biologics Market: Regional Profile
According to the global market report, North America accounted for significant share of the global market in 2022. This is ascribed to large geriatric population, increase in adoption of minimally invasive procedure, and rise in prevalence of spine disorders such as spondylolisthesis, spinal stenosis, and disc-related issues.
According to the American Association of Neurological Surgeons, an estimated 17,000 new cases of spinal cord injury are reported in the U.S. every year. Thus, a large spinal cord injury population is likely to drive demand for treatment of disorders, wherein spinal biologics plays an important role in diagnosis.
Asia Pacific is expected to witness significant spine biologics market expansion during the forecast period. This is ascribed to increase in geriatric population, rise in prevalence of spinal disorders, growing healthcare infrastructure, and improving access to advanced spinal treatments in countries such as China, India, and Japan.
Competitive Landscape
The spine biologics landscape is characterized by the presence of a substantial number of established market players. Companies focus on strategies such as new product launches, mergers, and partnerships & collaborations to compete in the marketplace. Some of the spine biologics service providers, as profiled by Transparency Market Research, include:
Johnson & Johnson (Depuy Synthes)
Orthofix Medical Inc.
Stryker Corporation
Zimmer Biomet
Arthrex Inc.
Exactech Inc.
Spine Wave Inc.
Medtronic Plc.
NuVasive Inc.
PUR Biologics (HippoFi Inc.)
Bone Biologics Corporation
Key Market Developments
In April 2023, PUR Biologics, a subsidiary of HippoFi, Inc., launched PURcore, a unique moldable synthetic with an interconnected micro-pore structure for spine surgery. PURcore allows for the rapid colonization of the patient’s own cells and growth factors which promotes bone regeneration and healing.
In February 2022, Orthofix Medical Inc. expanded the full market launch of Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures. Furthermore, Opus BA can be used to fill bone voids or gaps in the skeletal system that are not intrinsic to the stability of bony structure.
In April 2023, Bone Biologics Corporation received approval from the Human Research Ethics Committee (HREC) for the first of a planned multicenter pilot clinical trial to evaluate the company’s NB1 bone graft in Australia. This pilot study will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD).
logytwo
3年前
HippoFi's PUR Biologics Granted National Approval at the Veterans Health Administration (VHA), the Largest Integrated Healthcare System in the United States
The nation’s largest system includes 1,298 healthcare facilities
IRVINE, CA / June 27, 2023 / HippoFi, Inc. (OTCPK:ORHB) a leading healthcare technology company focused on the development and distribution of innovative biologic products, is proud to announce that its flagship subsidiary, PUR Biologics, has obtained national approval to sell its comprehensive portfolio of biologic products throughout the Veterans Health Administration (VHA). This milestone approval will further support the care of veterans within the largest integrated healthcare system in the United States.
The VHA currently serves over 9 million veterans enrolled in the VA health care program. With 1,298 healthcare facilities, including 171 VA Medical Centers and 1,113 outpatient sites of care, the VHA plays a crucial role in delivering comprehensive medical assistance to our nation's heroes.
PUR Biologics' diverse range of biologic products has met stringent quality standards and demonstrated results in various therapeutic areas. Through this new relationship with the VHA, PUR Biologics provides veterans with access to advanced treatment options that can improve their health outcomes and overall quality of life.
"We are thrilled to have received national approval to distribute our biologic products throughout the VHA," said Ryan Fernan, Head of PUR Biologics. "We are deeply committed to improving the health and well-being of our nation's veterans, this achievement with the VHA allows us to expand our impact and bring the benefits of our innovative biologics to those who have served our country."
CJ Wiggins, HippoFi's Executive Chairman and CEO, noted, "We could not be more excited about the Company's progress with sales. The VHA channel is set to serve as a major driver of sales for the Company and is our largest sales milestone achievement to date. PUR Biologics continues to add new distributors to our national sales network, including targeting those selling specifically to the VHA." Wiggins closed by stating, "Investors can expect to see HippoFi and PUR further its continued success as we anticipate announcing our achievement of several additional, and even more significant goals in the months ahead."
logytwo
3年前
PUR Biologics Begins Shipment of its Breakthrough Product PURbonedough(TM)
PURbonedough positioned to capture its share of the forecasted total spine market expected to grow from 13.3 billon in 2023 to 19 billion in 2030, a growth rate of 5.2% CAGR
PURbonedough is PURs most advanced product yet in bone regeneration, notably spinal fusion
Shipment has begun to distributors and customers with strong feedback; should be major seller in 2023
The products innovative dough-like consistency is superior in handling to currently available products
PUR Biologics, an innovative biotech company, and wholly-owned subsidiary of HippoFi, Inc. (OTC PINK: ORHB), today has unveiled its latest product, PURbonedough, to further expand its leadership into the burgeoning spine biologics market.
PURbonedough is derived from 100% donated human tissue that, through significant research and development, has been prepared to optimize the cellular conditions required for spine fusion surgeries. The product's unique composition also offers the best in market handling properties that provide confidence and assurance against graft migration.
At PUR Biologics, we are committed to developing innovative solutions that can improve patient surgical and functional outcomes, ultimately advancing patients' quality of life," said Ryan Fernan, Head of PUR Biologics.
With its extensive network of direct sales and strategic sales partners, nearing 300 sales representatives nationwide, PUR Biologics plans to launch PURbonedough and capture its share of the forecasted growth in the spine biologics market.
"We believe that PUR Biologics' continued investment in advanced biologic solutions will drive our growth and lead to long-term value creation for our shareholders." says CJ Wiggins, Founder, Executive Chairman & CEO of HippoFi.
To learn more about PURbonedough and PUR Biologics' full line of biologic products, visit www.PURbiologics.com.
----
logytwo
3年前
PUR Biologics Expands Sales Network by 15%, Adding 32 New Distributors
Press Release | 04/27/2023
IRVINE, CA / ACCESSWIRE / April 27, 2023 / HippoFi, Inc. (OTC PINK:ORHB), a leading healthcare innovator and technology company, is proud to announce the expansion of its biologics division, PUR Biologics. The addition of 32 new distributors to PUR Biologics' distribution network is a testament to the growing demand for its high-quality products and expertise in ortho-spine biologics. With these new distributors, PUR Biologics has significantly increased its reach and access to new customers, bringing its total number of distributors specializing in the surgical spine and orthopedic market to 239.
"We're excited to see PUR Biologics' continued growth and expansion," said HippoFi Founder, Executive Chairman & CEO, CJ Wiggins. "Our team's dedication and hard work is reflected in the addition of these new distributors."
PUR Biologics specializes in the development and sales of biologics that offer effective solutions to critical health problems. The company's management believes that the new distributors will have a positive impact on product sales as early as the second half of 2023, bringing valuable experience and expertise to the company.
"We're thrilled to partner with PUR Biologics and bring their innovative products to our customers," said Brooks Kieschnick, President of Dispersion Group. "Their commitment to quality and innovation aligns with our own values, and we look forward to working together to improve patient outcomes and advance the field of biologics."
PUR Biologics' success is due in part to its strong partnerships with leading product development organizations and broad sales channels, as well as its commitment to advancing technology and quality. "With the continued growth of our distribution network, industry-leading product pipeline, and breakthrough technologies, PUR Biologics is well-positioned to continue to lead this space and drive further growth in the biologics industry," said Ryan Fernan, Head of PUR Biologics.
HippoFi, Inc. is publicly traded under the symbol: ORHB and is headquartered in Irvine, California. For more information, please visit: www.HippoFi.com and www.PURbiologics.com.
logytwo
3年前
BALTIMORE, MD / ACCESSWIRE / April 20, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on HippoFi, Inc., formerly known as ORHub, Inc. (OTCPK:ORHB), a cutting-edge healthcare and fintech technology solutions provider. The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit: https://bit.ly/3LeZa05.
HippoFi, Inc. (formerly known as ORHub, Inc.), delivers cutting-edge healthcare and fintech innovations through an extensive sales channel network while implementing first-to-market solutions in the multi-billion-dollar regenerative therapeutics and digital payments markets. PUR Biologics®, HippoFi's Regenerative Therapeutic division, offers a portfolio of innovative biological products and proprietary technologies for bone growth in surgical spine procedures and advanced autologous cell therapies for regenerating cartilage in joints and spinal discs. HippoFi-Pay™, ORHB's Digital Payment division, is developing a novel business management software, which seeks to standardize processes at the point of surgical care with improved logistics and efficiencies.
In the Opportunity Research report, analyst Rob Goldman reviews ORHB's high sales growth in its Regenerative Therapeutics division, future product innovation and evolution, along with strategic and operational inflection points, and the potential future impact of these events on the company and its valuation.
ORHB Experiencing Unprecedented Top-Line Growth
Goldman commented, "Led by its PUR Biologics division, the Company has quickly become a go-to player in the multi-billion-dollar Regenerative Therapeutics market. The PUR product line features popular, innovative products serving unmet needs. The products are designed for use in spine procedures and advanced autologous cell therapies for regenerating cartilage in joints and spinal discs. Thus, we currently forecast June fiscal year sales will jump from $2.9M in FY23E to $28M in FY24E and $75M in FY25E. Plus, we project meaningful operating income to commence in FY24E."
Major Distributor Driving Sales, Ahead of New, Transformative Product Introductions
"ORHB's sales are driven by its distributor relationships, notably segment leader Precision Spine. The company's 207 sales distributors now offer the complete PUR biologic line to 280 hospitals and roughly 340 spine surgeons who perform 800 of these surgeries monthly," noted Goldman. "In addition, PUR has entered a new innovation and evolution phase, which features the development of transformative products that could be awarded 510(k) clearance in 2024."
Price Target Matches Peer Group Price/Sales Metric
"Our current 12+ month price target reflects a 4x price/revenue multiple on FY25E revenue, the same metric assigned to its peer group. We believe future upside to the target exists when taking into account a premium to FY25E sales and a 25x P/E on net income," concluded Goldman.
logytwo
3年前
US Patent Office Grants PUR Biologics' Breakthrough Patent for Activating Immune Cells
Press Release | 04/19/2023
Patent thrusts PUR Biologics into the $200B immunotherapy market
IRVINE, CA / ACCESSWIRE / April 19, 2023 / PUR Biologics, a wholly owned subsidiary of HippoFi (OTC PINK:ORHB) today announced the issuance of a groundbreaking technology which activates immune cells. This issued patent launches PUR Biologics into the field of cell and immune therapies, ushering in a new era of medical treatments for patients with immune compromised and chronic pain conditions. A 2022 Grand View Research study found the immunotherapy market value is projected to be worth $271.84 Billion USD by 2030.
"The increasing adoption of immunotherapies and technological advancements in bioinformatics will expand our growth opportunities," said CJ Wiggins, Executive Chairman & CEO of HippoFi. "We are pleased to support PUR Biologics' biotechnologies and restorative therapeutics as we continue to position ourselves as an authority in biologics and innovator in advanced cellular-based immunotherapies."
Immune therapies support the battle against degenerative and diseased conditions by developing new pathways to restore the immune system's capacity to heal as intended. PUR has been developing a variety of methods to activate the immune system and critical cells from the patient's bone marrow to mitigate neuropathic and centralized pain signals and the development of new anti-cancer therapeutics.
"We are proud to be at the forefront of this exciting new technology," said Ryan Fernan, Head of PUR Biologics. "By activating immune cells, we can unlock their full potential and create therapies that are more effective than ever before. PUR Biologics' innovative approach to utilizing this technology has the promise to improve the quality of life, particularly in our aging population."
HippoFi, Inc. is publicly traded under the symbol: ORHB and is headquartered in Irvine, California. For more information, please visit: www.HippoFi.com and www.PURbiologics.com.
logytwo
3年前
IRVINE, CA / ACCESSWIRE / April 13, 2023 / PUR Biologics, a wholly owned subsidiary of HippoFi, Inc
(OTC PINK:ORHB), is pleased to announce the release of PURfiberXP™, a uniquely processed demineralized extracellular matrix (d-ECM) designed to support bone regeneration, cellular integration, and patient healing"PURfiberXP™ is a highly specialized biologic derived from cortical bone fibers using a proprietary process," shared Ryan Fernan, Head of PUR Biologics. "The advanced surface design of PUR's fibers offers a complete interconnected matrix and promotes cell migration within the desired area of healing. FiberXP exhibits exceptional bone-forming capacity and is an ideal solution for enhancing bone regeneration in spine patients."
The global bone regeneration market is expected to experience significant growth in the coming years, driven by an increasing aging population, rising incidence of spine, orthopedic, and dental disorders, along with continued advancements in technology"As an innovator in the biologics industry, we are excited to introduce this technology, the latest addition to our full line of biologic product options," continued Fernan. "PURfiberXP™ provides exceptional handling and workability, enabling spine surgeons to effectively implant the advanced bioactive material in support of patients healing and bone regeneration."
PUR Biologics is committed to supporting hospitals and surgeons in providing the best care for their patients with state-of-the-art biologic products. With the launch of PURfiberXP™, PUR Biologics further solidifies its position as the premier spine and ortho biologic company.
For more information on PURfiberXP™ and PUR Biologics, please visit www.PURbiologics.com.
logytwo
3年前
HippoFi Announces Its Return to a Pink Current Information Tier on the OTC Market
IRVINE, CA / April 11, 2023 / HippoFi, Inc. (OTC Pink: ORHB), a diversified company focused on the biotech and fintech markets, is pleased to announce that it has achieved Pink Current status with the OTCMarkets, a major milestone in the company's growth and development.
Achieving this status is a testament to HippoFi's commitment to excellence and transparency. "We are incredibly proud to have achieved Pink Current status with OTCMarkets, which is a significant milestone in our journey to create long-term value for our shareholders," said CJ Wiggins, Executive Chairman & CEO of HippoFi. "This achievement would not have been possible without the hard work and dedication of our entire team, and we are grateful for their efforts."
Ryan Fernan, Head of PUR Biologics, a wholly owned subsidiary of HippoFi, added: "As a new member of the HippoFi team, I am excited to be a part of this milestone and confident in our ability to deliver profitable growth and strong results for our shareholders. The future looks phenomenal for HippoFi, and we are committed to continuing to drive innovation and success."
To achieve Pink Current status, HippoFi has systematically bolstered its business, refined its practices, and reorganized its operations. The company has implemented robust corporate governance, financial reporting, and internal controls, all of which have been instrumental in achieving compliance with OTCMarkets requirements.
This achievement sets the stage for HippoFi's future growth and expansion, and the company is excited about the opportunities ahead. HippoFi invites investors and shareholders to learn more about the company's vision, strategy, and plans for the future by visiting HippoFi.com.
logytwo
3年前
PUR Biologics Announces Launch of PURcore, a bioActive Moldable Synthetic for Spine Surgery[/
IRVINE, CA / April 6, 2023 / PUR Biologics, a subsidiary of HippoFi, Inc. (OTC Pink: ORHB), is proud to announce the launch of PURcoreTM, a unique moldable synthetic with an interconnected micro-pore structure for spine surgery. PURcoreTM allows for the rapid colonization of the patient's own cells and growth factors which promotes bone regeneration and healing.
As a subsidiary of HippoFi, PUR Biologics is committed to supporting hospitals and surgeon partners to provide the best care for their patients with a full line of biologic product options. With the launch of PURcoreTM, PUR Biologics continues to demonstrate its authority and commitment to becoming the best- in-class spinal biologic company.
"As a market leader in innovation, PUR Biologics is excited to offer PURcoreTM as another cutting-edge product to support patient care. PURcoreTM has remarkable handling properties and moldability, making it easy for spine surgeons to intraoperatively implant and keep this advanced bioActive material where the desired healing is to occur," shared CJ Wiggins, Executive Chairman & CEO of HippoFi.
logytwo
3年前
HippoFi Begins 2023 with Strong Sales of Advanced Biomaterials**
Expanded sales force fuels market growth.
IIRVINE, CA / January 12, 2023 / HippoFi, Inc. (formerly ORHub), (OTC Pink: ORHB), a diversified company focused on the biotech and fintech markets, launches 2023 with robust sales of its PUR Biologics line of products. “We have expanded our sales channels in the last 6 weeks by over 28% and anticipate this rapid growth to continue throughout the year. Customer demand is driving sales towards record highs as we continually help patients with our advanced biologic solutions. HippoFi’s Biotech division is well positioned to be a leader in biologics with our PUR Biologics offering and promising future technologies,” said CJ Wiggins, Executive Chairman & CEO of HippoFi, Inc.
“We are energized by the tremendous support and positive feedback we are receiving from our surgeon customers, strategic partners, and distributor channels. This exponential success in sales represents a growing momentum to capture significant market share over the next 12 months and is a credit to our outstanding team and our unique industry relationships,” stated Ryan Fernan, Head of PUR Biologics.
HippoFi is traded on the OTC under the symbol “ORHB”.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
BGCapital
2年前
BlazingStocks
3年前
Ther FUNKyMonkey
3年前
TrendTrade2016
3年前
メールアドレスで登録
